Literature DB >> 20642364

Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations.

Sarah E Flanagan1, Ann-Marie Patch, Sian Ellard.   

Abstract

CONTEXT: The interpretation of novel missense variants is a challenge with increasing numbers of such variants being identified and a responsibility to report the findings in the context of all available scientific evidence. Various in silico bioinformatic tools have been developed that predict the likely pathogenicity of missense variants; however, their utility within the diagnostic setting requires further investigation. AIM: The aim of our study was to test the predictive value of two of these tools, sorting intolerant from tolerant (SIFT) and polymorphism phenotyping (PolyPhen), in a set of 141 missense variants (131 pathogenic, 8 benign) identified in the ABCC8, GCK, and KCNJ11 genes.
METHODS: Sixty-six of the mutations caused a gain of protein function, while 67 were loss-of-function mutations. The evolutionary conservation at each residue was also investigated using multiple sequence alignments from the UCSC genome browser.
RESULTS: The sensitivity of SIFT and PolyPhen was reasonably high (69% and 68%, respectively), but their specificity was low (13% and 16%). Both programs were significantly better at predicting loss-of-function mutations than gain-of-function mutations (SIFT, p = 0.001; PolyPhen, p < or = 0.0001). The most reliable method for assessing the likely pathogenicity of a missense variant was to investigate the degree of conservation at the affected residue. Eighty-eight percent of the mutations affected highly conserved residues, while all of the benign variants occurred at residues that were polymorphic across multiple species.
CONCLUSIONS: Although SIFT and PolyPhen may be useful in prioritizing changes that are likely to cause a loss of protein function, their low specificity means that their predictions should be interpreted with caution and further evidence to support/refute pathogenicity should be sought before reporting novel missense changes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20642364     DOI: 10.1089/gtmb.2010.0036

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  146 in total

1.  Homozygous splice mutation in CWF19L1 in a Turkish family with recessive ataxia syndrome.

Authors:  Randi Burns; Karen Majczenko; Jishu Xu; Weiping Peng; Zuhal Yapici; James J Dowling; Jun Z Li; Margit Burmeister
Journal:  Neurology       Date:  2014-10-31       Impact factor: 9.910

2.  Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa.

Authors:  Morne Du Plessis; Brendon Pearce; Clifford Jacobs; Nisreen Hoosain; Mongi Benjeddou
Journal:  Mol Biol Rep       Date:  2014-11-15       Impact factor: 2.316

3.  Histoimmunogenetics Markup Language 1.0: Reporting next generation sequencing-based HLA and KIR genotyping.

Authors:  Robert P Milius; Michael Heuer; Daniel Valiga; Kathryn J Doroschak; Caleb J Kennedy; Yung-Tsi Bolon; Joel Schneider; Jane Pollack; Hwa Ran Kim; Nezih Cereb; Jill A Hollenbach; Steven J Mack; Martin Maiers
Journal:  Hum Immunol       Date:  2015-08-28       Impact factor: 2.850

4.  Genome-wide Associations Reveal Human-Mouse Genetic Convergence and Modifiers of Myogenesis, CPNE1 and STC2.

Authors:  Ana I Hernandez Cordero; Natalia M Gonzales; Clarissa C Parker; Greta Sokolof; David J Vandenbergh; Riyan Cheng; Mark Abney; Andrew Sko; Alex Douglas; Abraham A Palmer; Jennifer S Gregory; Arimantas Lionikas
Journal:  Am J Hum Genet       Date:  2019-11-21       Impact factor: 11.025

Review 5.  Standardized decision support in next generation sequencing reports of somatic cancer variants.

Authors:  Rodrigo Dienstmann; Fei Dong; Darrell Borger; Dora Dias-Santagata; Leif W Ellisen; Long P Le; A John Iafrate
Journal:  Mol Oncol       Date:  2014-04-04       Impact factor: 6.603

6.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.

Authors:  Lesley-Ann Sutton; Viktor Ljungström; Larry Mansouri; Emma Young; Diego Cortese; Veronika Navrkalova; Jitka Malcikova; Alice F Muggen; Martin Trbusek; Panagiotis Panagiotidis; Frederic Davi; Chrysoula Belessi; Anton W Langerak; Paolo Ghia; Sarka Pospisilova; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

7.  Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies.

Authors:  Chengliang Dong; Peng Wei; Xueqiu Jian; Richard Gibbs; Eric Boerwinkle; Kai Wang; Xiaoming Liu
Journal:  Hum Mol Genet       Date:  2014-12-30       Impact factor: 6.150

8.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

9.  Complexity and diversity of F8 genetic variations in the 1000 genomes.

Authors:  J N Li; I G Carrero; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

10.  Exome analysis of a family with Wolff-Parkinson-White syndrome identifies a novel disease locus.

Authors:  Neil E Bowles; Chuanchau J Jou; Cammon B Arrington; Brett J Kennedy; Aubree Earl; Norisada Matsunami; Lindsay L Meyers; Susan P Etheridge; Elizabeth V Saarel; Steven B Bleyl; H Joseph Yost; Mark Yandell; Mark F Leppert; Martin Tristani-Firouzi; Peter J Gruber
Journal:  Am J Med Genet A       Date:  2015-08-18       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.